In Phase III Data Merck’s GARDASIL® Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18

Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 -Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Naïve to the Relevant HPV Type

WHITEHOUSE STATION, N.J.--()--Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

“We are excited to learn more about the potential of GARDASIL to help prevent HPV and HPV-related cancers and diseases in both men and women,” said Richard M. Haupt, M.D., MPH, executive director, Merck Research Laboratories.

GARDASIL is approved in the U.S. for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the U.S. for use in boys and men ages 9 through 26 years of age for the prevention of genital warts (condylomata acuminata) caused by HPV types 6 and 11.

It is estimated that HPV types 16 and 18 account for 70 percent of cervical and vaginal cancer cases, and up to 50 percent of vulvar cancer cases and 85 percent of anal cancer cases. Types 6 and 11 cause approximately 90 percent of all genital warts cases.

Data on efficacy against intra anal disease

The ability of GARDASIL to prevent HPV 6, 11, 16 and 18-AIN and anal cancer in males was evaluated in a randomized, double-blind, placebo-controlled trial. A total of 598 16- to 26- year old men who have sex with men received at least one dose of GARDASIL or placebo at the time of enrollment, and then again at two and six months.

This evaluation of efficacy of GARDASIL against HPV-related anal disease was conducted in a population of men having sex with men because of the known high risk of anal infection that occurs in this group.

The per-protocol efficacy (PPE) population was the pre-defined primary population for this study. As defined, this group included men who were not infected with the relevant HPV vaccine type at the start of the study, and who did not become infected with that HPV vaccine type during the course of the vaccination series (seronegative and HPV DNA-negative to the relevant HPV vaccine type at day one, and HPV DNA-negative through the vaccination series to month seven). The cases of the primary endpoint of AIN and anal cancer were counted starting after month seven with an average follow up of 2.5 years.

In this PPE analysis, GARDASIL prevented 77.5 percent (95 percent CI: 39.6, 93.3) of HPV 6, 11, 16, and 18-related AIN and anal cancer. A total of 29 men were diagnosed with HPV 6, 11, 16 or 18-related AIN during the study, with 24 cases in the placebo group and five in the vaccine group. No cases of HPV 11 or 18-related AIN were observed in the vaccine group. No cases of anal cancer were seen in either the placebo or vaccine group.

In the study, 69 percent of the vaccine group and 64 percent of the placebo group reported one or more adverse events (AEs). These were predominantly injection-site AEs (60 percent of the vaccine group and 54 percent of the placebo group). Serious adverse events were reported rarely and occurred comparably in the vaccine (0.4 percent) and placebo (0.6 percent) groups, and none were deemed to be vaccine-related by the study investigators.

48 month end of study data for use of GARDASIL in women ages 24 through 45 also presented

A separate, double-blind, placebo-controlled study was designed to evaluate the ability of GARDASIL to prevent HPV 6,11,16,18-related persistent infection, cervical and genital disease in women ages 24 through 45. The study enrolled 3,817 women with no history of cervical disease, Loop Electrosurgical Excision Procedure (LEEP), hysterectomy or genital warts in the past five years. The women in the study received GARDASIL (n=1910) or placebo (n=1907) at day one and again at months two and six. HPV-related infection, cervical and genital disease was monitored every six months with Pap testing, genital inspection and cervicovaginal sampling.

In this new end-of-study per protocol efficacy analysis of women naïve to the respective vaccine types when they entered the study, GARDASIL was 88.7 percent (95 percent CI: 78.1.; 94.8) efficacious against persistent infection, CIN or EGL (including vulvar intraepithelial neoplasia [VIN], vaginal intraepithelial neoplasia [VaIN] and condyloma) associated with HPV types 6, 11, 16 and 18.

In this study, 87 percent of the vaccine group and 81 percent of the placebo group reported one or more AEs. These were predominantly injection-site AEs (77 percent of the vaccine group and 64 percent of the placebo group). Serious adverse events were reported rarely and occurred comparably in the vaccine (0.7 percent) and placebo (0.8 percent) groups, and none were deemed to be vaccine-related by the study investigators.

HPV: a virus that affects both men and women

HPV is a common virus. There are more than 40 types of HPV that are passed on through genital contact – most often during vaginal and anal sex. Most sexually active people, including more than half of American men, will have HPV at some time in their lives. According to the Centers for Disease Control and Prevention (CDC), in the U.S. alone, an estimated 20 million men and women are currently infected with HPV, and another 6.2 million people become newly infected each year.

"For most people, HPV does not cause any long-term clinical problems, however for some women, certain types of HPV can cause cervical cancer, vulvar cancer and vaginal cancer. In men and women these same types can also cause anal cancer and other types can lead to the development of genital warts. Nearly 5,000 people are diagnosed with anal cancer each year in the US," said Joel Palefsky, M.D. University of California San Francisco. In the US, it is estimated in 2009, that approximately 11,200 new cases of invasive cervical cancer were expected to be diagnosed, in addition to 2,100 new cases of vaginal cancer and 3,500 new cases of vulvar cancer.

Important information about GARDASIL[Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant]

GARDASIL is approved in the U.S. for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the U.S. for use in boys and men ages 9 through 26 years of age for the prevention of genital warts (condylomata acuminata) caused by HPV types 6 and 11.

GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening.

GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] has not been demonstrated to provide protection against diseases from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity.

GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, and vaginal cancers; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.

GARDASIL has not been demonstrated to protect against disease due to HPV types not contained in the vaccine.

Not all vulvar and vaginal cancers are caused by HPV, and GARDASIL protects only against those vulvar and vaginal cancers caused by HPV Types 16 and 18.

Select safety information

GARDASIL is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL.

Because vaccines may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.

GARDASIL is not recommended for use in pregnant women.

The most common adverse reaction was headache. Common adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0 percent and greater than placebo were: fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus and bruising.

Dosage and administration for GARDASIL

GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The following dosage schedule is recommended: First dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

GARDASIL is approved in 119 countries

GARDASIL (sold in some countries as SILGARD®) has been approved in 119 countries, and additional applications are currently under review with regulatory agencies in many more countries around the world.

About Merck

Today’s Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit www.merck.com.

Forward Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2008 Annual Report on Form 10-K, Schering-Plough’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2009, the proxy statement filed by Merck on June 25, 2009 and each company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site:( www.sec.gov.)

Prescribing Information and Patient Product Information for GARDASIL® are attached and is also available at www.gardasil.com.

GARDASIL® is a registered trademark of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.

9883612

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use GARDASIL safely and effectively. See full prescribing information for GARDASIL.

GARDASIL

[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Suspension for intramuscular injection

Initial U.S. Approval: 2006

--------------- RECENT MAJOR CHANGES ---------------

Indications and Usage (1)  
Girls and Women (1.1) 10/2009
Boys and Men (1.2) 10/2009
Limitations of GARDASIL Use and Effectiveness (1.3) 05/2009
Warnings and Precautions (5)
Syncope (5.1) 06/2009

--------------- INDICATIONS AND USAGE ---------------

GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11

And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:

  • Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS)
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3

GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11. (1)

Limitations of GARDASIL Use and Effectiveness

  • GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. (1.3) (17.1)
  • GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity. (1.3) (14.3) (14.4)
  • GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, and vaginal cancers; CIN; VIN; or VaIN. (1.3)
  • GARDASIL has not been demonstrated to protect against diseases due to HPV types not contained in the vaccine. (1.3) (14.5)
  • Not all vulvar and vaginal cancers are caused by HPV, and GARDASIL protects only against those vulvar and vaginal cancers caused by HPV 16 and 18. (1.3)
  • GARDASIL does not protect against genital diseases not caused by HPV. (1.3)
  • Vaccination with GARDASIL may not result in protection in all vaccine recipients. (1.3)

--------------- DOSAGE AND ADMINISTRATION ---------------

0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months. (2.1)

--------------- DOSAGE FORMS AND STRENGTHS ---------------

  • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe (3) (11)

--------------- CONTRAINDICATIONS ---------------

  • Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL. (4) (11)

--------------- WARNINGS AND PRECAUTIONS ---------------

  • Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position. (5.1)

--------------- ADVERSE REACTIONS ---------------

The most common adverse reaction was headache. Common adverse reactions (frequency of at least 1.0% and greater than AAHS control or saline placebo) are fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus, and bruising. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Merck & Co., Inc. at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

--------------- DRUG INTERACTIONS ---------------

GARDASIL may be administered concomitantly with RECOMBIVAX HB. (7.1)

--------------- USE IN SPECIFIC POPULATIONS ---------------

Safety and effectiveness of GARDASIL have not been established in the following populations:

  • Pregnant women. Physicians are encouraged to register pregnant women exposed to GARDASIL by calling 1-800-986-8999 so that Merck can monitor maternal and fetal outcomes. (8.1)
  • Children below the age of 9 years. (8.4)
  • Immunocompromised individuals. Response to GARDASIL may be diminished. (8.6)
  • Individuals 27 years of age and older. (8.1) (14.6)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 10/2009

 
 

FULL PRESCRIBING INFORMATION: CONTENTS*

1

   

INDICATIONS AND USAGE

1.1 Girls and Women
1.2 Boys and Men

 

1.3 Limitations of GARDASIL Use and Effectiveness

2

DOSAGE AND ADMINISTRATION

2.1 Dosage
2.2 Method of Administration

3

DOSAGE FORMS AND STRENGTHS

4

CONTRAINDICATIONS

5

WARNINGS AND PRECAUTIONS

5.1 Syncope
5.2 Managing Allergic Reactions

6

ADVERSE REACTIONS

6.1 Clinical Trials Experience
6.2 Postmarketing Experience

7

DRUG INTERACTIONS

7.1 Use with RECOMBIVAX HB
7.2 Use with Hormonal Contraceptives
7.3 Use with Systemic Immunosuppressive Medications

8

USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Immunocompromised Individuals

10

OVERDOSAGE

11

DESCRIPTION

12

CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

13

NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14

CLINICAL STUDIES

14.1 Prophylactic Efficacy – HPV Types 6, 11, 16, and 18 in Girls and Women 16 Through 26 Years of Age
14.2 Prophylactic Efficacy – HPV Types 6, 11, 16, and 18 in Boys and Men 16 Through 26 Years of Age
14.3 Population Impact in Girls and Women 16 Through 26 Years of Age
14.4 Population Impact in Boys and Men 16 Through 26 Years of Age
14.5 Overall Population Impact
14.6 Other Studies
14.7 Immunogenicity
14.8 Studies with RECOMBIVAX HB

16

HOW SUPPLIED/STORAGE AND HANDLING

17

PATIENT COUNSELING INFORMATION

17.1 Information for the Patient, Parent, or Guardian
17.2 FDA-Approved Patient Labeling
 

*Sections or subsections omitted from the full prescribing information are not listed.

 

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Girls and Women

GARDASIL®1 is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11

And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:

  • Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS)
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3

1.2 Boys and Men

GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11.

1.3 Limitations of GARDASIL Use and Effectiveness

The health care provider should inform the patient, parent, or guardian that vaccination does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care. [See Patient Counseling Information (17.1).]

GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity. [See Clinical Studies (14.3, 14.4).]

GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, and vaginal cancers; CIN; VIN; or VaIN.

GARDASIL has not been demonstrated to protect against diseases due to HPV types not contained in the vaccine. [See Clinical Studies (14.5).]

Not all vulvar and vaginal cancers are caused by HPV, and GARDASIL protects only against those vulvar and vaginal cancers caused by HPV 16 and 18.

GARDASIL does not protect against genital diseases not caused by HPV.

Vaccination with GARDASIL may not result in protection in all vaccine recipients.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage

GARDASIL should be administered intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months. [See Clinical Studies (14.7).]

2.2 Method of Administration

For intramuscular use only.

Shake well before use. Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine. GARDASIL should not be diluted or mixed with other vaccines. After thorough agitation, GARDASIL is a white, cloudy liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the product if particulates are present or if it appears discolored.

GARDASIL should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh.

Syncope has been reported following vaccination with GARDASIL and may result in falling with injury; observation for 15 minutes after administration is recommended. [See Warnings and Precautions (5.1).]

Single-Dose Vial Use

Withdraw the 0.5-mL dose of vaccine from the single-dose vial using a sterile needle and syringe and use promptly.

Prefilled Syringe Use With and Without Needle Guard (Safety) Device

Prefilled Syringe With Needle Guard (Safety) Device

Instructions for using the prefilled single-dose syringes preassembled with needle guard (safety) device

(Graphic Omitted)

NOTE: Please use the enclosed needle for administration. If a different needle is chosen, it should fit securely on the syringe and be no longer than 1 inch to ensure proper functioning of the needle guard device. Two detachable labels are provided which can be removed after the needle is guarded.

At any of the following steps, avoid contact with the Trigger Fingers to keep from activating the safety device prematurely.

Remove Syringe Tip Cap and Needle Cap. Attach Luer Needle by pressing both Anti-Rotation Tabs to secure syringe and by twisting the Luer Needle in a clockwise direction until secured to the syringe. Remove Needle Sheath. Administer injection per standard protocol as stated above under DOSAGE AND ADMINISTRATION. Depress the Plunger while grasping the Finger Flange until the entire dose has been given. The Needle Guard Device will NOT activate to cover and protect the needle unless the ENTIRE dose has been given. While the Plunger is still depressed, remove needle from the vaccine recipient. Slowly release the Plunger and allow syringe to move up until the entire needle is guarded. For documentation of vaccination, remove detachable labels by pulling slowly on them. Dispose in approved sharps container.

Prefilled Syringe Without Needle Guard (Safety) Device

This package does not contain a needle guard (safety device) or a needle. Shake well before use. Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose as per standard protocol.

3 DOSAGE FORMS AND STRENGTHS

GARDASIL is a suspension for intramuscular administration available in 0.5-mL single dose vials and prefilled syringes. See Description (11) for the complete listing of ingredients.

4 CONTRAINDICATIONS

Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL. [See Description (11).]

5 WARNINGS AND PRECAUTIONS

5.1 Syncope

Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position.

5.2 Managing Allergic Reactions

Appropriate medical treatment and supervision must be readily available in case of anaphylactic reactions following the administration of GARDASIL.

6 ADVERSE REACTIONS

Overall Summary of Adverse Reactions

Headache, fever, nausea, and dizziness; and local injection site reactions (pain, swelling, erythema, pruritus, and bruising) occurred after administration with GARDASIL.

Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL and may result in falling with injury; observation for 15 minutes after administration is recommended. [See Warnings and Precautions (5.1).]

Anaphylaxis has been reported following vaccination with GARDASIL.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

Studies in Girls, Women, Boys, and Men 9 Through 26 Years of Age

In 6 clinical trials (4 Amorphous Aluminum Hydroxyphosphate Sulfate [AAHS]-controlled, 1 saline placebo-controlled, and 1 uncontrolled), 14,273 individuals were administered GARDASIL or AAHS control or saline placebo on the day of enrollment, and approximately 2 and 6 months thereafter, and safety was evaluated using vaccination report cards (VRC)-aided surveillance for 14 days after each injection of GARDASIL or AAHS control or saline placebo in these individuals. The individuals who were monitored using VRC-aided surveillance included 8180 individuals 9 through 26 years of age at enrollment who received GARDASIL and 6093 individuals who received AAHS control or saline placebo. Few individuals (0.2%) discontinued due to adverse reactions. The race distribution of the girls and women in the safety population was as follows: 62.3% White; 17.6% Hispanic (Black and White); 6.8% Asian; 6.7% Other; 6.4% Black; and 0.3% American Indian. The race distribution of the boys and men in the safety population was as follows: 42.0% White; 19.7% Hispanic (Black and White); 11.0% Asian; 11.2% Other; 15.9% Black; and 0.1% American Indian.

Common Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age

The injection site adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients are shown in Table 1.

Table 1

Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age*

 

Adverse Reaction

(1 to 5 Days Postvaccination)

GARDASIL

(N = 5088)

%

AAHS Control**

(N = 3470)

%

Saline

Placebo

(N = 320)

%

Injection Site

Pain 83.9 75.4 48.6
Swelling 25.4 15.8 7.3
Erythema 24.7 18.4 12.1
Pruritus 3.2 2.8 0.6
Bruising 2.8 3.2 1.6
*The injection-site adverse reactions that were observed among recipients of GARDASIL were at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients.

**AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Common Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age

The injection site adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients are shown in Table 2.

Table 2

Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age*

 

Adverse Reaction

(1 to 5 Days Postvaccination)

GARDASIL

(N = 3092)

%

AAHS Control **

(N = 2029)

%

Saline

Placebo

(N = 274)

%

Injection Site

Pain 61.5 50.8 41.6
Erythema 16.7 14.1 14.5
Swelling 13.9 9.6 8.2
*The injection-site adverse reactions that were observed among recipients of GARDASIL were at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients.

**AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Evaluation of Injection-Site Adverse Reactions by Dose in Girls and Women 9 Through 26 Years of Age

An analysis of injection-site adverse reactions in girls and women by dose is shown in Table 3. Of those girls and women who reported an injection-site reaction, 94.3% judged their injection-site adverse reaction to be mild or moderate in intensity.

Table 3

Postdose Evaluation of Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age

(1 to 5 Days Postvaccination)

    GARDASIL

(% occurrence)

  AAHS Control*

(% occurrence)

  Saline Placebo

(% occurrence)

Adverse

Reaction

  Post-

dose

1

N** = 5011

  Post-

dose

2

N = 4924

  Post-

dose

3

N = 4818

  Post-

dose

1

N = 3410

  Post-

dose

2

N = 3351

  Post-

dose

3

N = 3295

  Post-

dose

1

N = 315

  Post-

dose

2

N = 301

  Post-

dose

3

N = 300

Pain

  63.4   60.7   62.7   57.0   47.8   49.6   33.7   20.3   27.3
Mild/Moderate 62.5 59.7 61.2 56.6 47.3 48.9 33.3 20.3 27.0
Severe   0.9   1.0   1.5   0.4   0.5   0.6   0.3   0.0   0.3

Swelling***

10.2 12.8 15.1 8.2 7.5 7.6 4.4 3.0 3.3
Mild/Moderate 9.6 11.9 14.2 8.1 7.2 7.3 4.4 3.0 3.3
Severe   0.6   0.8   0.9   0.2   0.2   0.2   0.0   0.0   0.0

Erythema***

9.2 12.1 14.7 9.8 8.4 8.9 7.3 5.3 5.7
Mild/Moderate 9.0 11.7 14.3 9.5 8.4 8.8 7.3 5.3 5.7
Severe   0.2   0.3   0.4   0.3   0.1   0.1   0.0   0.0   0.0
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate
**N = Number of individuals with follow-up

***Intensity of swelling and erythema was measured by size (inches): Mild = 0 to ≤1; Moderate = >1 to ≤2; Severe = >2.

Evaluation of Injection-Site Adverse Reactions by Dose in Boys and Men 9 Through 26 Years of Age

An analysis of injection-site adverse reactions in boys and men by dose is shown in Table 4. Of those boys and men who reported an injection-site reaction, 96.4% judged their injection-site adverse reaction to be mild or moderate in intensity.

Table 4

Postdose Evaluation of Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age

(1 to 5 Days Postvaccination)

    GARDASIL

(% occurrence)

  AAHS Control*

(% occurrence)

  Saline Placebo

(% occurrence)

Adverse

Reaction

  Post-

dose

1

N** = 3002

  Post-

dose

2

N = 2897

  Post-

dose

3

N = 2825

  Post-

dose

1

N = 1950

  Post-

dose

2

N = 1853

  Post-

dose

3

N = 1799

  Post-

dose

1

N = 269

  Post-

dose

2

N = 263

  Post-

dose

3

N = 259

Pain

  44.7   36.9   34.4   38.4   28.2   25.8   27.5   20.5   16.2
Mild/Moderate 44.5 36.5 34.1 37.9 28.2 25.5 27.5 20.2 16.2
Severe   0.2   0.5   0.3   0.4   0.1   0.3   0.0   0.4   0.0

Swelling***

5.6 6.6 7.7 5.6 4.5 4.1 4.8 1.5 3.5
Mild/Moderate 5.3 6.2 7.1 5.4 4.5 4.0 4.8 1.5 3.1
Severe   0.2   0.3   0.5   0.2   0.0   0.1   0.0   0.0   0.4

Erythema***

7.2 8.0 8.7 8.3 6.3 5.7 7.1 5.7 5.0
Mild/Moderate 6.8 7.7 8.3 8.0 6.2 5.6 7.1 5.7 5.0
Severe   0.3   0.2   0.3   0.2   0.1   0.1   0.0   0.0   0.0
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate
**N = Number of individuals with follow-up
***Intensity of swelling and erythema was measured by size (inches): Mild = 0 to ≤1; Moderate = >1 to ≤2; Severe = >2.

Common Systemic Adverse Reactions in Girls and Women 9 Through 26 Years of Age

Headache was the most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 28.2% and AAHS control or saline placebo = 28.4%). Fever was the next most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 13.0% and AAHS control or saline placebo = 11.2%).

Adverse reactions that were observed among recipients of GARDASIL, at a frequency of greater than or equal to 1.0% where the incidence in the GARDASIL group was greater than or equal to the incidence in the AAHS control or saline placebo group, are shown in Table 5.

Table 5

Common Systemic Adverse Reactions in Girls and Women 9 Through 26 Years of Age (GARDASIL ≥ Control)*

Adverse Reactions

(1 to 15 Days Postvaccination)

  GARDASIL

(N = 5088)

%

  AAHS control** or Saline Placebo

(N = 3790)

%

Pyrexia   13.0   11.2
Nausea 6.7 6.5
Dizziness 4.0 3.7
Diarrhea 3.6 3.5
Vomiting 2.4 1.9
Cough 2.0 1.5
Toothache 1.5 1.4
Upper respiratory tract infection 1.5 1.5
Malaise 1.4 1.2
Arthralgia 1.2 0.9
Insomnia 1.2 0.9
Nasal congestion   1.1   0.9

*The adverse reactions in this table are those that were observed among recipients of GARDASIL at a frequency

 of at least 1.0% and greater than or equal to those observed among AAHS control or saline placebo recipients.

**AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Common Systemic Adverse Reactions in Boys and Men 9 Through 26 Years of Age

Headache was the most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 12.3% and AAHS control or saline placebo = 11.2%). Fever was the next most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 8.2% and AAHS control or saline placebo = 6.5%).

Adverse reactions that were observed among recipients of GARDASIL, at a frequency of greater than or equal to 1.0% where the incidence in the group that received GARDASIL was greater than or equal to the incidence in the AAHS control or saline placebo group, are shown in Table 6.

Table 6

Common Systemic Adverse Reactions in Boys and Men 9 Through 26 Years of Age (GARDASIL ≥ Control)*

Adverse Reactions

(1 to 15 Days Postvaccination)

  GARDASIL

(N = 3092)

%

  AAHS control** or Saline Placebo

(N = 2303)

%

Headache   12.3   11.2
Pyrexia 8.2 6.5
Pharyngolaryngeal pain 2.8 2.1
Diarrhea 2.7 2.2
Nasopharyngitis 2.6 2.6
Nausea 2.0 1.0
Upper respiratory tract infection 1.5 1.0
Abdominal pain upper 1.4 1.4
Myalgia 1.3 0.7
Dizziness 1.2 0.9
Vomiting   1.0   0.8

*The adverse reactions in this table are those that were observed among recipients of GARDASIL at a frequency

 of at least 1.0% and greater than or equal to those observed among AAHS control or saline placebo recipients.

**AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Evaluation of Fever by Dose in Girls and Women 9 Through 26 Years of Age

An analysis of fever in girls and women by dose is shown in Table 7.

Table 7

Postdose Evaluation of Fever in Girls and Women 9 Through 26 Years of Age

(1 to 5 Days Postvaccination)

    GARDASIL

(% occurrence)

  AAHS Control* or Saline Placebo

(% occurrence)

Temperature

(°F)

  Postdose 1

N** = 4945

  Postdose 2

N = 4804

  Postdose 3

N = 4671

  Postdose 1

N = 3681

  Postdose 2

N = 3564

  Postdose 3

N = 3467

≥100 to <102   3.7   4.1   4.4   3.1   3.8   3.6
≥102   0.3   0.5   0.5   0.2   0.4   0.5
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate
**N = Number of individuals with follow-up

Evaluation of Fever by Dose in Boys and Men 9 Through 26 Years of Age

An analysis of fever in boys and men by dose is shown in Table 8.

Table 8

Postdose Evaluation of Fever in Boys and Men 9 Through 26 Years of Age

(1 to 5 Days Postvaccination)

    GARDASIL

(% occurrence)

  AAHS Control* or Saline Placebo

(% occurrence)

Temperature

(°F)

  Postdose 1

N** = 2971

  Postdose 2

N = 2847

  Postdose 3

N = 2791

  Postdose 1

N = 2194

  Postdose 2

N = 2079

  Postdose 3

N = 2046

≥100 to <102   2.4   2.5   2.3   2.1   2.1   1.6
≥102   0.6   0.5   0.5   0.6   0.3   0.3
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate
**N = Number of individuals with follow-up

Serious Adverse Reactions in the Entire Study Population

Across the clinical studies, 255 individuals (GARDASIL N = 126 or 0.8%; Placebo N = 129 or 1.0%) out of 29,323 (GARDASIL N = 15,706; AAHS control N = 13,023; or saline placebo N = 594) individuals (9- through 45-year-old girls and women; and 9- through 26-year-old boys and men) reported a serious systemic adverse reaction.

Of the entire study population (29,323 individuals), 0.04% of the reported serious systemic adverse reactions were judged to be vaccine related by the study investigator. The most frequently (frequency of 4 cases or greater with either GARDASIL, AAHS control, saline placebo, or the total of all three) reported serious systemic adverse reactions, regardless of causality, were:

Headache [0.02% GARDASIL (3 cases) vs. 0.02% AAHS Control (2 cases)],
Gastroenteritis [0.02% GARDASIL (3 cases) vs. 0.02% AAHS Control (2 cases)],
Appendicitis [0.03% GARDASIL (5 cases) vs. 0.01% AAHS Control (1 case)],
Pelvic inflammatory disease [0.02% GARDASIL (3 cases) vs. 0.03% AAHS Control (4 cases)],
Urinary tract infection [0.01% GARDASIL (2 cases) vs. 0.02% AAHS Control (2 cases)],
Pneumonia [0.01% GARDASIL (2 cases) vs. 0.02% AAHS Control (2 cases)],
Pyelonephritis [0.01% GARDASIL (2 cases) vs. 0.02% AAHS Control (3 cases)],
Pulmonary embolism [0.01% GARDASIL (2 cases) vs. 0.02% AAHS Control (2 cases)].

One case (0.006% GARDASIL; 0.0% AAHS Control or Saline Placebo) of bronchospasm; and 2 cases
(0.01% GARDASIL; 0.0% AAHS Control or Saline Placebo) of asthma were reported as serious systemic
adverse reactions that occurred following any vaccination visit.

In addition, there was 1 individual in the clinical trials, in the group that received GARDASIL, who reported two injection-site serious adverse reactions (injection-site pain and injection-site joint movement impairment).

Deaths in the Entire Study Population

Across the clinical studies, 37 deaths (GARDASIL N = 18 or 0.1%; Placebo N = 19 or 0.1%) were reported in 29,323 (GARDASIL N = 15,706; AAHS Control N = 13,023, saline placebo N = 594) individuals (9- through 45-year-old girls and women; and 9- through 26-year-old boys and men). The events reported were consistent with events expected in healthy adolescent and adult populations. The most common cause of death was motor vehicle accident (5 individuals who received GARDASIL and 4 individuals who received AAHS Control), followed by drug overdose/suicide (2 individuals who received GARDASIL and 6 individuals who received AAHS Control), gun shot wound (1 individual who received GARDASIL and 3 individuals who received AAHS Control), and pulmonary embolus/deep vein thrombosis (1 individual who received GARDASIL and 1 individual who received AAHS Control). In addition, there were 2 cases of sepsis, 1 case of pancreatic cancer, 1 case of arrhythmia, 1 case of pulmonary tuberculosis, 1 case of hyperthyroidism, 1 case of post-operative pulmonary embolism and acute renal failure, 1 case of traumatic brain injury/cardiac arrest, and 1 case of systemic lupus erythematosus in the group that received GARDASIL; 1 case of asphyxia, 1 case of acute lymphocytic leukemia, 1 case of chemical poisoning, and 1 case of myocardial ischemia in the AAHS Control group; and 1 case of medulloblastoma in the saline placebo group.

Systemic Autoimmune Disorders in Girls and Women 9 Through 26 Years of Age

In the clinical studies, 9- through 26-year-old girls and women were evaluated for new medical conditions that occurred over the course of follow-up. New medical conditions potentially indicative of a systemic autoimmune disorder seen in the group that received GARDASIL or AAHS control or saline placebo are shown in Table 9. This population includes all girls and women who received at least one dose of GARDASIL or AAHS control or saline placebo, and had safety data available.

Table 9

Summary of Girls and Women 9 Through 26 Years of Age Who Reported an Incident Condition
Potentially Indicative of a Systemic Autoimmune Disorder After Enrollment in Clinical Trials of
GARDASIL, Regardless of Causality

Conditions GARDASIL

(N = 10,706)

AAHS Control* or Saline Placebo

(N = 9412)

n (%) n (%)
Arthralgia/Arthritis/Arthropathy** 120 (1.1) 98 (1.0)
Autoimmune Thyroiditis 4 (0.0) 1 (0.0)
Celiac Disease 10 (0.1) 6 (0.1)
Diabetes Mellitus Insulin-dependent 2 (0.0) 2 (0.0)
Erythema Nodosum 2 (0.0) 4 (0.0)
Hyperthyroidism*** 27 (0.3) 21 (0.2)
Hypothyroidism(†) 35 (0.3) 38 (0.4)
Inflammatory Bowel Disease(‡) 7 (0.1) 10 (0.1)
Multiple Sclerosis 2 (0.0) 4 (0.0)
Nephritis(¶) 2 (0.0) 5 (0.1)
Optic Neuritis 2 (0.0) 0 (0.0)
Pigmentation Disorder(§) 4 (0.0) 3 (0.0)
Psoriasis(#) 13 (0.1) 15 (0.2)
Raynaud's Phenomenon 3 (0.0) 4 (0.0)
Rheumatoid Arthritis(††) 6 (0.1) 2 (0.0)
Scleroderma/Morphea 2 (0.0) 1 (0.0)
Stevens-Johnson Syndrome 1 (0.0) 0 (0.0)
Systemic Lupus Erythematosus 1 (0.0) 3 (0.0)
Uveitis 3 (0.0) 1 (0.0)
All Conditions 245 (2.3) 218 (2.3)
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

**Arthralgia/Arthritis/Arthropathy includes the following terms: Arthralgia, Arthritis, Arthritis reactive, and Arthropathy

***Hyperthyroidism includes the following terms: Basedow's disease, Goiter, Toxic nodular goiter, and Hyperthyroidism

(†)Hypothyroidism includes the following terms: Hypothyroidism and thyroiditis
(‡)Inflammatory bowel disease includes the following terms: Colitis ulcerative, Crohn's disease, and Inflammatory bowel disease
(¶)Nephritis includes the following terms: Nephritis, Glomerulonephritis minimal lesion, Glomerulonephritis proliferative
(§)Pigmentation disorder includes the following terms: Pigmentation disorder, Skin depigmentation, and Vitiligo

(#)Psoriasis includes the following terms: Psoriasis, Pustular psoriasis, and Psoriatic arthropathy

(††)Rheumatoid arthritis includes juvenile rheumatoid arthritis. One woman counted in the rheumatoid arthritis group reported
rheumatoid arthritis as an adverse experience at Day 130.

N = Number of individuals enrolled
n = Number of individuals with specific new Medical Conditions

NOTE: Although an individual may have had two or more new Medical Conditions, the individual is counted only once within

 a category. The same individual may appear in different categories.

Systemic Autoimmune Disorders in Boys and Men 9 Through 26 Years of Age

In the clinical studies, 9- through 26-year-old boys and men were evaluated for new medical conditions that occurred over the course of follow-up. New medical conditions potentially indicative of a systemic autoimmune disorder seen in the group that received GARDASIL or AAHS control or saline placebo are shown in Table 10. This population includes all boys and men who received at least one dose of GARDASIL or AAHS control or saline placebo, and had safety data available.

Table 10

Summary of Boys and Men 9 Through 26 Years of Age Who Reported an Incident Condition
Potentially Indicative of a Systemic Autoimmune Disorder After Enrollment in Clinical Trials of
GARDASIL, Regardless of Causality

Conditions

GARDASIL

(N = 3092)

AAHS Control* or Saline Placebo

(N = 2303)

n (%) n (%)
Alopecia Areata 1 (0.0) 0 (0.0)
Ankylosing Spondylitis 1 (0.0) 2 (0.1)
Arthralgia/Arthritis/Reactive Arthritis 30 (1.0) 17 (0.7)
Autoimmune Thrombocytopenia 1 (0.0) 0 (0.0)
Diabetes Mellitus Type 1 3 (0.1) 2 (0.1)
Hyperthyroidism 0 (0.0) 1 (0.0)
Hypothyroidism** 3 (0.1) 0 (0.0)
Inflammatory Bowel Disease*** 0 (0.0) 2 (0.1)
Myocarditis 1 (0.0) 1 (0.0)
Proteinuria 1 (0.0) 0 (0.0)
Psoriasis 0 (0.0) 2 (0.1)
Vitiligo 2 (0.1) 5 (0.2)
All Conditions 43 (1.4) 32 (1.4)
*AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate
**Hypothyroidism includes the following terms: Hypothyroidism and Autoimmune thyroiditis
***Inflammatory bowel disease includes the following terms: Colitis ulcerative and Crohn's disease
N = Number of individuals who received at least one dose of either vaccine or placebo
n = Number of individuals with specific new Medical Conditions

NOTE: Although an individual may have had two or more new Medical Conditions, the individual is counted only once within
 a category. The same individual may appear in different categories.

Safety in Concomitant Use with RECOMBIVAX HB in Girls and Women 9 Through 26 Years of Age

The safety of GARDASIL when administered concomitantly with RECOMBIVAX HB hepatitis B vaccine (recombinant) was evaluated in an AAHS-controlled study of 1871 girls and women with a mean age of 20.4 years. The race distribution of the study individuals was as follows: 61.6% White; 23.8% Other; 11.9% Black; 1.6% Hispanic (Black and White); 0.8% Asian; and 0.3% American Indian. The rates of systemic and injection-site adverse reactions were similar among girls and women who received concomitant vaccination as compared with those who received GARDASIL or RECOMBIVAX HB hepatitis B vaccine.

6.2 Postmarketing Experience

The following adverse events have been spontaneously reported during post-approval use of GARDASIL. Because these events were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish a causal relationship to vaccine exposure.

Blood and lymphatic system disorders: Autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, lymphadenopathy.
Respiratory, thoracic and mediastinal disorders: Pulmonary embolus.
Gastrointestinal disorders: Nausea, pancreatitis, vomiting.
General disorders and administration site conditions: Asthenia, chills, death, fatigue, malaise.
Immune system disorders: Autoimmune diseases, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse myelitis.
Vascular disorders: Deep venous thrombosis.

7 DRUG INTERACTIONS

7.1 Use with RECOMBIVAX HB

Results from clinical studies indicate that GARDASIL may be administered concomitantly (at a separate injection site) with RECOMBIVAX HB hepatitis B vaccine (recombinant) [see Clinical Studies (14.8)]. Co-administration of GARDASIL with other vaccines has not been studied.

7.2 Use with Hormonal Contraceptives

In clinical studies, 13,293 women (GARDASIL N = 6644; AAHS control or saline placebo N = 6649) who had post-Month 7 follow-up used hormonal contraceptives for a total of 17,597 person-years (65.1% of the total follow-up time in the studies). Use of hormonal contraceptives or lack of use of hormonal contraceptives among study participants did not alter immune response in the per protocol efficacy (PPE) population.

7.3 Use with Systemic Immunosuppressive Medications

Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines [see Use in Specific Populations (8.6)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B:

Reproduction studies have been performed in female rats at doses equivalent to the recommended human dose and have revealed no evidence of impaired female fertility or harm to the fetus due to GARDASIL. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, GARDASIL should be used during pregnancy only if clearly needed.

An evaluation of the effect of GARDASIL on embryo-fetal, pre- and postweaning development was conducted using rats. One group of rats was administered GARDASIL twice prior to gestation, during the period of organogenesis (gestation Day 6) and on lactation Day 7. A second group of pregnant rats was administered GARDASIL during the period of organogenesis (gestation Day 6) and on lactation Day 7 only. GARDASIL was administered at 0.5 mL/rat/occasion (120 mcg total protein which is equivalent to the recommended human dose) by intramuscular injection. No adverse effects on mating, fertility, pregnancy, parturition, lactation, embryo-fetal or pre- and postweaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study. In addition, there were no treatment-related effects on developmental signs, behavior, reproductive performance, or fertility of the offspring.

Clinical Studies in Humans

In clinical studies, women underwent urine pregnancy testing prior to administration of each dose of GARDASIL. Women who were found to be pregnant before completion of a 3-dose regimen of GARDASIL were instructed to defer completion of their vaccination regimen until resolution of the pregnancy.

GARDASIL is not indicated for women 27 years of age or older. However, safety data in women 16 through 45 years of age was collected, and 3620 women (GARDASIL N = 1796 vs. AAHS control or saline placebo N = 1824) reported at least 1 pregnancy each.

The overall proportions of pregnancies that resulted in an adverse outcome, defined as the combined numbers of spontaneous abortion, late fetal death, and congenital anomaly cases out of the total number of pregnancy outcomes for which an outcome was known (and excluding elective terminations), were 23.3% (423/1812) in women who received GARDASIL and 24.1% (438/1820) in women who received AAHS control or saline placebo.

Overall, 54 and 63 women in the group that received GARDASIL or AAHS control or saline placebo, respectively (3.0% and 3.5% of all women who reported a pregnancy in the respective vaccination groups), experienced a serious adverse reaction during pregnancy. The most common events reported were conditions that can result in Caesarean section (e.g., failure of labor, malpresentation, cephalopelvic disproportion), premature onset of labor (e.g., threatened abortions, premature rupture of membranes), and pregnancy-related medical problems (e.g., pre-eclampsia, hyperemesis). The proportions of pregnant women who experienced such events were comparable between the groups receiving GARDASIL and AAHS control or saline placebo.

There were 40 cases of congenital anomaly in pregnancies that occurred in women who received GARDASIL and 30 cases of congenital anomaly in pregnancies that occurred in women who received AAHS control or saline placebo.

Further sub-analyses were conducted to evaluate pregnancies with estimated onset within 30 days or more than 30 days from administration of a dose of GARDASIL or AAHS control or saline placebo. For pregnancies with estimated onset within 30 days of vaccination, 5 cases of congenital anomaly were observed in the group that received GARDASIL compared to 1 case of congenital anomaly in the group that received AAHS control or saline placebo. The congenital anomalies seen in pregnancies with estimated onset within 30 days of vaccination included pyloric stenosis, congenital megacolon, congenital hydronephrosis, hip dysplasia, and club foot. Conversely, in pregnancies with onset more than 30 days following vaccination, 35 cases of congenital anomaly were observed in the group that received GARDASIL compared with 29 cases of congenital anomaly in the group that received AAHS control or saline placebo.

Pregnancy Registry for GARDASIL

Merck & Co., Inc. maintains a Pregnancy Registry to monitor fetal outcomes of pregnant women exposed to GARDASIL. Patients and health care providers are encouraged to report any exposure to GARDASIL during pregnancy by calling (800) 986-8999.

8.3 Nursing Mothers

Women 16 Through 26 Years of Age

It is not known whether GARDASIL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GARDASIL is administered to a nursing woman.

A total of 995 nursing mothers (vaccine N = 500, AAHS control N = 495) were given GARDASIL or AAHS control during the vaccination period of the clinical trials.

Overall, 21 and 10 infants of women who received GARDASIL or AAHS control, respectively (representing 4.2% and 2.0% of the total number of women who were breast-feeding during the period in which they received GARDASIL or AAHS control, respectively), experienced a serious adverse reaction.

In a post-hoc analysis of clinical studies, a higher number of breast-feeding infants (n = 6) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post-vaccination of the mother as compared to infants (n = 2) whose mothers received AAHS control. In these studies, the rates of other adverse reactions in the mother and the nursing infant were comparable between vaccination groups.

8.4 Pediatric Use

Safety and effectiveness have not been established in pediatric patients below 9 years of age.

8.5 Geriatric Use

The safety and effectiveness of GARDASIL have not been evaluated in a geriatric population, defined as individuals aged 65 years and over.

8.6 Immunocompromised Individuals

The immunologic response to GARDASIL may be diminished in immunocompromised individuals [see Drug Interactions (7.3)].

10 OVERDOSAGE

There have been reports of administration of higher than recommended doses of GARDASIL.

In general, the adverse event profile reported with overdose was comparable to recommended single doses of GARDASIL.

11 DESCRIPTION

GARDASIL, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, is a non-infectious recombinant quadrivalent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs. The fermentation process involves growth of S. cerevisiae on chemically-defined fermentation media which include vitamins, amino acids, mineral salts, and carbohydrates. The VLPs are released from the yeast cells by cell disruption and purified by a series of chemical and physical methods. The purified VLPs are adsorbed on preformed aluminum-containing adjuvant (Amorphous Aluminum Hydroxyphosphate Sulfate). The quadrivalent HPV VLP vaccine is a sterile liquid suspension that is prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer.

GARDASIL is a sterile suspension for intramuscular administration. Each 0.5-mL dose contains approximately 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein.

Each 0.5-mL dose of the vaccine contains approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, <7 mcg yeast protein/dose, and water for injection. The product does not contain a preservative or antibiotics.

After thorough agitation, GARDASIL is a white, cloudy liquid.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Human beings develop a humoral immune response to the vaccine, although the exact mechanism of protection is unknown.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

GARDASIL has not been evaluated for the potential to cause carcinogenicity or genotoxicity.

GARDASIL administered to female rats at a dose of 120 mcg total protein, which is equivalent to the recommended human dose, had no effects on mating performance, fertility, or embryonic/fetal survival.

The effect of GARDASIL on male fertility has been studied in male rats at an intramuscular dose of 0.5 mL/rat/occasion (120 mcg total protein which is equivalent to the recommended human dose). One group of male rats was administered GARDASIL once, 3 days prior to cohabitation, and a second group of male rats was administered GARDASIL three times, at 6 weeks, 3 weeks, and 3 days prior to cohabitation. There were no treatment-related effects on reproductive performance including fertility, sperm count, and sperm motility. There were no treatment-related gross or histomorphologic and weight changes on the testes.

14 CLINICAL STUDIES

CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma of the cervix, respectively. Their detection and removal has been shown to prevent cancer; thus, they serve as surrogate markers for prevention of cervical cancer. In the clinical studies in girls and women aged 16 through 26 years, cases of CIN 2/3 and AIS were the efficacy endpoints to assess prevention of cervical cancer. In addition, cases of VIN 2/3 and VaIN 2/3 were the efficacy endpoints to assess prevention of HPV-related vulvar and vaginal cancers, and observations of external genital lesions were the efficacy endpoints for the prevention of genital warts.

In clinical studies in boys and men aged 16 through 26 years, efficacy was evaluated using the following endpoints: external genital warts and penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3 or penile/perineal/perianal cancer.

Efficacy was assessed in 5 AAHS-controlled, double-blind, randomized Phase II and III clinical studies. The first Phase II study evaluated the HPV 16 component of GARDASIL (Study 1, N = 2391 girls and women) and the second evaluated all components of GARDASIL (Study 2, N = 551 girls and women). Two Phase III studies evaluated GARDASIL in 5442 (Study 3) and 12,157 (Study 4) girls and women. A third Phase III study, Study 5, evaluated GARDASIL in 4055 boys and men. Together, these five studies evaluated 24,596 individuals (20,541 girls and women 16 through 26 years of age at enrollment with a mean age of 20.0 years and 4055 boys and men 16 through 26 years of age at enrollment with a mean age of 20.5 years). The race distribution of the girls and women in the clinical trials was as follows: 70.4% White; 12.2% Hispanic (Black and White); 8.8% Other; 4.6% Black; 3.8% Asian; and 0.2% American Indian. The race distribution of the boys and men in the clinical trials was as follows: 35.2% White; 20.5% Hispanic (Black and White); 14.4% Other; 19.8% Black; 10.0% Asian; and 0.1% American Indian.

The median duration of follow-up was 4.0, 3.0, 3.0, 3.0, and 2.3 years for Study 1, Study 2, Study 3, Study 4, and Study 5, respectively. Individuals received vaccine or AAHS control on the day of enrollment and 2 and 6 months thereafter. Efficacy was analyzed for each study individually and for all studies in girls and women combined according to a prospective clinical plan.

Overall, 73% of 16- through 26-year-old girls and women and 83% of 16- through 26-year-old boys and men were naïve (i.e., PCR [Polymerase Chain Reaction] negative and seronegative for all 4 vaccine HPV types) to all 4 vaccine HPV types at enrollment.

A total of 27% of 16- through 26-year-old girls and women and 17% of 16- through 26-year-old boys and men had evidence of prior exposure to or ongoing infection with at least 1 of the 4 vaccine HPV types. Among these individuals, 74% of 16- through 26-year-old girls and women and 78% of 16- through 26-year-old boys and men had evidence of prior exposure to or ongoing infection with only 1 of the 4 vaccine HPV types and were naïve (PCR negative and seronegative) to the remaining 3 types.

In individuals who were naïve (PCR negative and seronegative) to all 4 vaccine HPV types, CIN, genital warts, VIN, VaIN, PIN, and persistent infection caused by any of the 4 vaccine HPV types were counted as endpoints.

Among individuals who were positive (PCR positive and/or seropositive) for a vaccine HPV type at Day 1, endpoints related to that type were not included in the analyses of prophylactic efficacy. Endpoints related to the remaining types for which the individual was naïve (PCR negative and seronegative) were counted.

For example, in individuals who were HPV 18 positive (PCR positive and/or seropositive) at Day 1, lesions caused by HPV 18 were not counted in the prophylactic efficacy evaluations. Lesions caused by HPV 6, 11, and 16 were included in the prophylactic efficacy evaluations. The same approach was used for the other types.

14.1 Prophylactic Efficacy – HPV Types 6, 11, 16, and 18 in Girls and Women 16 Through 26 Years of Age

GARDASIL was administered without prescreening for presence of HPV infection and the efficacy trials allowed enrollment of girls and women regardless of baseline HPV status (i.e., PCR status or serostatus). Girls and women with current or prior HPV infection with an HPV type contained in the vaccine were not eligible for prophylactic efficacy evaluations for that type.

The primary analyses of efficacy with respect to HPV types 6, 11, 16, and 18 were conducted in the per-protocol efficacy (PPE) population, consisting of girls and women who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative in cervicovaginal specimens and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy was measured starting after the Month 7 visit.

GARDASIL was efficacious in reducing the incidence of CIN (any grade including CIN 2/3); AIS; genital warts; VIN (any grade); and VaIN (any grade) related to vaccine HPV types 6, 11, 16, or 18 in those who were PCR negative and seronegative at baseline (Table 11).

In addition, girls and women who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from precancerous cervical lesions and external genital lesions caused by the other vaccine HPV types.

Table 11

Analysis of Efficacy of GARDASIL in the PPE* Population** of 16- Through 26-Year-Old Girls and Women for Vaccine HPV Types

Population GARDASIL AAHS Control % Efficacy (95% CI)
N Number of cases N Number of cases
HPV 16- or 18-related CIN 2/3 or AIS
Study 1*** 755 0 750 12 100.0 (65.1, 100.0)
Study 2 231 0 230 1 100.0 (-3744.9, 100.0)
Study 3 2201 0 2222 36 100.0 (89.2, 100.0)
Study 4 5306 2 5262 63 96.9 (88.2, 99.6)
Combined Protocols 8493 2 8464 112 98.2 (93.5, 99.8)
HPV 16-related CIN 2/3 or AIS
Combined Protocols 7402 2 7205 93 97.9 (92.3, 99.8)
HPV 18-related CIN 2/3 or AIS
Combined Protocols 7382 0 7316 29 100.0 (86.6, 100.0)
HPV 16- or 18-related VIN 2/3
Study 2 231 0 230 0 Not calculated
Study 3 2219 0 2239 6 100.0 (14.4, 100.0)
Study 4 5322 0 5275 4 100.0 (-50.3, 100.0)
Combined Protocols 7772 0 7744 10 100.0 (55.5, 100.0)
HPV 16- or 18-related VaIN 2/3
Study 2 231 0 230 0 Not calculated
Study 3 2219 0 2239 5 100.0 (-10.1, 100.0)
Study 4 5322 0 5275 4 100.0 (-50.3, 100.0)
Combined Protocols 7772 0 7744 9 100.0 (49.5, 100.0)
HPV 6-, 11-, 16-, or 18-related CIN (CIN 1, CIN 2/3) or AIS
Study 2 235 0 233 3 100.0 (-138.4, 100.0)
Study 3 2241 0 2258 77 100.0 (95.1, 100.0)
Study 4 5388 9 5374 145 93.8 (88.0, 97.2)
Combined Protocols 7864 9 7865 225 96.0 (92.3, 98.2)
HPV 6-, 11-, 16-, or 18-related Genital Warts
Study 2 235 0 233 3 100.0 (-139.5, 100.0)
Study 3 2261 0 2279 58 100.0 (93.5, 100.0)
Study 4 5404 2 5390 132 98.5 (94.5, 99.8)
Combined Protocols 7900 2 7902 193 99.0 (96.2, 99.9)
HPV 6- and 11-related Genital Warts
Combined Protocols 6932 2 6856 189 99.0 (96.2, 99.9)

*The PPE population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations

 from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to

 dose 1 and through 1 month postdose 3 (month 7).

**See Table 13 for analysis of vaccine impact in the general population.
***Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL
(‡)Analyses of the combined trials were prospectively planned and included the use of similar study entry criteria
N = Number of individuals with at least 1 follow-up visit after Month 7
CI = Confidence Interval
Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up

Note 2: The first analysis in the table (i.e., HPV 16- or 18-related CIN 2/3, AIS or worse) was the primary endpoint of the vaccine

 development plan.

Note 3: Table 11 does not include cases due to non-vaccine HPV types.
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Prophylactic efficacy against overall cervical and genital disease related to HPV 6, 11, 16, and 18 in an extension phase of Study 2, that included data through month 60, was noted to be 100% (95% CI: 12.3%, 100.0%) among girls and women in the per protocol population naïve to the relevant HPV types.

GARDASIL was efficacious against HPV disease caused by HPV types 6, 11, 16, and 18 in girls and women who were naïve for those specific HPV types at baseline.

14.2 Prophylactic Efficacy – HPV Types 6, 11, 16, and 18 in Boys and Men 16 Through 26 Years of Age

The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population. This population consisted of boys and men who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (month 7). Efficacy was measured starting after the Month 7 visit.

GARDASIL was efficacious in reducing the incidence of genital warts related to vaccine HPV types 6 and 11 in those boys and men who were PCR negative and seronegative at baseline (Table 12). Efficacy against penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3 or penile/perineal/perianal cancer was not demonstrated as the number of cases was too limited to reach statistical significance.

Table 12

Analysis of Efficacy of GARDASIL in the PPE Population of 16- Through 26-Year-Old Boys and Men for Vaccine HPV Types

Endpoint   GARDASIL   AAHS Control   % Efficacy (95% CI)
  N*   Number of cases   N   Number of cases  
External Genital Lesions HPV 6-, 11-, 16-, or 18- related
External Genital Lesions   1397   3   1408   31   90.4 (69.2, 98.1)
Condyloma   1397   3   1408   28   89.4 (65.5, 97.9)
PIN 1/2/3   1397   0   1408   3   100 (-141.2, 100.0)
*N = Number of individuals with at least 1 follow-up visit after Month 7
CI = Confidence Interval
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

14.3 Population Impact in Girls and Women 16 Through 26 Years of Age

Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types

The clinical trials included girls and women regardless of current or prior exposure to vaccine HPV types, and additional analyses were conducted to evaluate the impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related cervical and genital disease in these girls and women. Here, analyses included events arising among girls and women regardless of baseline PCR status and serostatus, including HPV infections that were present at the start of vaccination as well as events that arose from infections that were acquired after the start of vaccination.

The impact of GARDASIL in girls and women regardless of current or prior exposure to a vaccine HPV type is shown in Table 13. Impact was measured starting 1 month Postdose 1. Prophylactic efficacy denotes the vaccine’s efficacy in girls and women who are naïve (PCR negative and seronegative) to the relevant HPV types at Day 1. Vaccine impact in girls and women who were positive for vaccine HPV infection, as well as vaccine impact among girls and women regardless of baseline vaccine HPV PCR status and serostatus are also presented. The majority of CIN and genital warts, VIN, and VaIN related to a vaccine HPV type detected in the group that received GARDASIL occurred as a consequence of HPV infection with the relevant HPV type that was already present at Day 1.

There was no clear evidence of protection from disease caused by HPV types for which girls and women were PCR positive regardless of serostatus at baseline.

Table 13

Effectiveness of GARDASIL in Prevention of HPV 6, 11, 16, or 18 Related Genital Disease in Girls and
Women 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types

Endpoint   Analysis   GARDASIL or HPV 16 L1 VLP Vaccine   AAHS Control   % Reduction
(95% CI)
    N   Cases   N   Cases  
HPV 16- or 18-related CIN 2/3 or AIS Prophylactic Efficacy*   9346   4   9407   155   97.4 (93.3, 99.3)
HPV 16 and/or HPV 18 Positive at Day 1   2870   142   2898   148**   --***
  Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18   9836   146   9904   303   51.8 (41.1, 60.7)
HPV 16- or 18-related VIN 2/3 or VaIN 2/3 Prophylactic Efficacy*   8642   1   8673   34   97.0 (82.4, 99.9)
HPV 16 and/or HPV 18 Positive at Day 1   1880   8   1876   4   --***
  Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18   8955   9   8968   38   76.3 (50.0, 89.9)
HPV 6-, 11-, 16-, 18-related CIN (CIN 1, CIN 2/3) or AIS Prophylactic Efficacy*   8630   16   8680   309   94.8 (91.5, 97.1)
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1   2466   186#   2437   213#   --***
  Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types   8819   202   8854   522   61.5 (54.6, 67.4)
HPV 6-, 11-, 16-, or 18-related Genital Warts Prophylactic Efficacy*   8761   10   8792   252   96.0 (92.6, 98.1)
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1   2501   51§   2475   55§   --***
  Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types   8955   61   8968   307   80.3 (73.9, 85.3)
HPV 6- or 11-related Genital Warts Prophylactic Efficacy*   7769   9   7792   246   96.4 (93.0, 98.4)
HPV 6 and/or HPV 11 Positive at Day 1   1186   51   1176   54   --***
  Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types   8955   60   8968   300   80.1 (73.7, 85.2)

*Includes all individuals who received at least 1 vaccination and who were naïve (PCR negative and seronegative) to HPV 6, 11, 16, and/or

18 at Day 1. Case counting started at 1 month postdose 1.

**Out of the 148 AAHS control cases of 16/18 CIN 2/3, 2 women were missing serology or PCR results for Day 1.

***There is no expected efficacy since GARDASIL has not been demonstrated to provide protection against disease from vaccine HPV

types to which a person has previously been exposed through sexual activity.

(†)Includes all individuals who received at least 1 vaccination (regardless of baseline HPV status at Day 1). Case counting started at 1 month postdose 1.

(‡)Percent reduction includes the prophylactic efficacy of GARDASIL as well as the impact of GARDASIL on the course of infections present at the start of the vaccination.

(#)Includes 2 AAHS control women with missing serology/PCR data at Day 1.

(§)Includes 1 woman with missing serology/PCR data at Day 1.

CI = Confidence Interval

N = Number of individuals who have at least one follow-up visit after Day 1

Note 1: The 16- and 18-related CIN 2/3 or AIS composite endpoint included data from studies 1, 2, 3, and 4. All other endpoints only

included data from studies 2, 3, and 4.

Note 2: Positive status at Day 1 denotes PCR positive and/or seropositive for the respective type at Day 1.

Note 3: Table 13 does not include disease due to non-vaccine HPV types.

AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Infection with Vaccine or Non-Vaccine HPV Types

The impact of GARDASIL against the overall burden of HPV-related cervical, vulvar, and vaginal disease (i.e., disease caused by any HPV type) results from a combination of prophylactic efficacy against vaccine HPV types, disease contribution from vaccine HPV types present at time of vaccination, and the disease contribution from HPV types not contained in the vaccine.

Additional efficacy analyses were conducted in 2 populations: (1) a generally HPV-naïve population (negative to 14 common HPV types and had a Pap test that was negative for SIL [Squamous Intraepithelial Lesion] at Day 1), approximating a population of sexually-naïve girls and women and (2) the general study population of girls and women regardless of baseline HPV status, some of whom had HPV-related disease at Day 1.

Among generally HPV-naïve girls and women and among all girls and women in the study population (including girls and women with HPV infection at Day 1), GARDASIL reduced the overall incidence of CIN 2/3 or AIS; of VIN 2/3 or VaIN 2/3; of CIN (any grade) or AIS; and of Genital Warts (Table 14). These reductions were primarily due to reductions in lesions caused by HPV types 6, 11, 16, and 18 in girls and women naïve (seronegative and PCR negative) for the specific relevant vaccine HPV type. Infected girls and women may already have CIN 2/3 or AIS at Day 1 and some will develop CIN 2/3 or AIS during follow-up, either related to a vaccine or non-vaccine HPV type present at the time of vaccination or related to a non-vaccine HPV type not present at the time of vaccination.

Table 14

Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Girls and Women 16
Through 26 Years of Age, Regardless of Current or Prior Infection with Vaccine or Non-Vaccine HPV Types

Endpoints Caused by Vaccine or Non-vaccine HPV Types   Analysis   GARDASIL   AAHS Control   % Reduction
(95% CI)
    N   Cases   N   Cases  
CIN 2/3 or AIS Prophylactic Efficacy*   4616   77   4680   136   42.7 (23.7, 57.3)
  Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   8559   421   8592   516   18.4 (7.0, 28.4)***
VIN 2/3 and VaIN 2/3 Prophylactic Efficacy*   4688   7   4735   31   77.1 (47.1, 91.5)
  Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   8688   30   8701   61   50.7 (22.5, 69.3)***
CIN (Any Grade) or AIS Prophylactic Efficacy*   4616   272   4680   390   29.7 (17.7, 40.0)
  Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   8559   967   8592   1189   19.1 (11.9, 25.8)***
Genital Warts Prophylactic Efficacy*   4688   29   4735   169   82.8 (74.3, 88.8)
  Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   8688   132   8701   350   62.5 (54.0, 69.5)***

*Includes all individuals who received at least 1 vaccination and who had a Pap test that was negative for SIL [Squamous Intraepithelial
Lesion] at Day 1 and were naïve to 14 common HPV types at Day 1. Case counting started at 1 month postdose 1.

**Includes all individuals who received at least 1 vaccination (regardless of baseline HPV status or Pap test result at Day 1). Case
counting started at 1 month postdose 1.

***Percent reduction includes the prophylactic efficacy of GARDASIL as well as the impact of GARDASIL on the course of infections
present at the start of the vaccination.

CI = Confidence Interval
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

14.4 Population Impact in Boys and Men 16 Through 26 Years of Age

Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Genital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types

Study 5 included boys and men regardless of current or prior exposure to vaccine HPV types, and additional analyses were conducted to evaluate the impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related genital disease in these boys and men. Here, analyses included events arising among boys and men regardless of baseline PCR status and serostatus, including HPV infections that were present at the start of vaccination as well as events that arose from infections that were acquired after the start of vaccination.

The impact of GARDASIL in boys and men regardless of current or prior exposure to a vaccine HPV type is shown in Table 15. Impact was measured starting at Day 1. Prophylactic efficacy denotes the vaccine’s efficacy in boys and men who are naïve (PCR negative and seronegative) to the relevant HPV types at Day 1. Vaccine impact in boys and men who were positive for vaccine HPV infection, as well as vaccine impact among boys and men regardless of baseline vaccine HPV PCR status and serostatus are also presented. The majority of genital disease related to a vaccine HPV type detected in the group that received GARDASIL occurred as a consequence of HPV infection with the relevant HPV type that was already present at Day 1.

There was no clear evidence of protection from disease caused by HPV types for which boys and men were PCR positive regardless of serostatus at baseline.

Table 15

Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Genital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types

Endpoint   Analysis   GARDASIL   AAHS

Control

  % Reduction

(95% CI)

    N   Cases   N   Cases    
External Genital Lesions Prophylactic Efficacy*   1775   13   1770   52   75.5 (54.3, 87.7)
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1   168   14   167   25   --**
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types***   1943   27   1937   77   65.5 (45.8, 78.6)
Condyloma Prophylactic Efficacy*   1775   10   1770   48   79.6 (59.1, 90.8)
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1   168   14   167   24   --**
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types***   1943   24   1937   72   67.2 (47.3, 80.3)
PIN 1/2/3 Prophylactic Efficacy*   1775   4   1770   4   1.2 (-430.5, 81.6)
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1   168   2   167   1   --**
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types***   1943   6   1937   5   -19.2 (-393.8, 69.7)
*Includes all individuals who received at least 1 vaccination and who were HPV-naïve (i.e., seronegative and PCR negative) at Day 1 to the vaccine HPV type being analyzed. Case counting started at Day 1.
**There is no expected efficacy since GARDASIL has not been demonstrated to provide protection against disease from vaccine HPV types to which a person has previously been exposed through sexual activity.
***Includes all individuals who received at least 1 vaccination. Case counting started at Day 1.
(†)Percent reduction for these analyses includes the prophylactic efficacy of GARDASIL as well as the impact of GARDASIL on the course of infections present at the start of the vaccination.
CI = Confidence Interval
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Infection with Vaccine or Non-Vaccine HPV Types

The impact of GARDASIL against the overall burden of HPV-related genital disease (i.e., disease caused by any HPV type) results from a combination of prophylactic efficacy against vaccine HPV types, disease contribution from vaccine HPV types present at time of vaccination, and the disease contribution from HPV types not contained in the vaccine.

Additional efficacy analyses from Study 5 were conducted in 2 populations: (1) a generally HPV-naïve population that consisted of boys and men who are seronegative and PCR negative to HPV 6, 11, 16, and 18 and PCR-negative to HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 at Day 1, approximating a population of sexually-naïve boys and men and (2) the general study population of boys and men regardless of baseline HPV status, some of whom had HPV-related disease at Day 1.

Among generally HPV-naïve boys and men and among all boys and men in Study 5 (including boys and men with HPV infection at Day 1), GARDASIL reduced the overall incidence of genital disease (Table 16). These reductions were primarily due to reductions in lesions caused by HPV types 6, 11, 16, and 18 in boys and men naïve (seronegative and PCR negative) for the specific relevant vaccine HPV type. Infected boys and men may already have genital disease at Day 1 and some will develop genital disease during follow-up, either related to a vaccine or non-vaccine HPV type present at the time of vaccination or related to a non-vaccine HPV type not present at the time of vaccination.

Table 16

Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Infection with Vaccine or Non-Vaccine HPV Types

Endpoint   Analysis   GARDASIL   AAHS

Control

  % Reduction (95% CI)
    N   Cases   N   Cases  
External Genital Lesions Generally HPV Naïve*   1275   6   1270   36   83.8 (61.2, 94.4)
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   1943   36   1937   89   60.2 (40.8, 73.8)***
Condyloma Generally HPV Naïve*   1275   5   1270   33   85.3 (62.1, 95.5)
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   1943   32   1937   83   62.1 (42.4, 75.6)***
PIN 1/2/3 Generally HPV Naïve*   1275   1   1270   3   67.4 (-306.5, 99.4)
  Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types**   1943   7   1937   6   -15.9 (-317.5, 66.6)***
*Includes all individuals who received at least 1 vaccination and who were seronegative and PCR negative at enrollment to HPV 6, 11, 16 and 18, and PCR-negative at enrollment to HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. Case counting started at Day 1.
**Includes all individuals who received at least 1 vaccination. Case counting started at Day 1.
***Percent reduction for these analyses includes the prophylactic efficacy of GARDASIL as well as the impact of GARDASIL on the course of infections present at the start of the vaccination.
CI = Confidence Interval
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate

14.5 Overall Population Impact

The subject characteristics (e.g. lifetime sex partners, geographic distribution of the subjects) influence the HPV prevalence of the population and therefore the population benefit can vary widely.

The overall efficacy of GARDASIL will vary with the baseline prevalence of HPV infection and disease, the incidence of infections against which GARDASIL has shown protection, and those infections against which GARDASIL has not been shown to protect.

The efficacy of GARDASIL for HPV types not included in the vaccine (i.e., cross-protective efficacy) is a component of the overall impact of the vaccine on rates of disease caused by HPV. Cross-protective efficacy was not demonstrated against disease caused by non-vaccine HPV types in the combined database of the Study 3 and Study 4 trials.

GARDASIL does not protect against genital disease not related to HPV. One woman who received GARDASIL in Study 3 developed an external genital well-differentiated squamous cell carcinoma at month 24. No HPV DNA was detected in the lesion or in any other samples taken throughout the study.

In 18,150 girls and women enrolled in Study 2, Study 3, and Study 4, GARDASIL reduced definitive cervical therapy procedures by 23.9% (95% CI: 15.2%, 31.7%).

14.6 Other Studies

Data are insufficient to establish effectiveness of GARDASIL in women 27 through 45 years of age.

14.7 Immunogenicity

Assays to Measure Immune Response

The minimum anti-HPV titer that confers protective efficacy has not been determined.

Because there were few disease cases in individuals naïve (PCR negative and seronegative) to vaccine HPV types at baseline in the group that received GARDASIL, it has not been possible to establish minimum anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 antibody levels that protect against clinical disease caused by HPV 6, 11, 16, and/or 18.

The immunogenicity of GARDASIL was assessed in 20,132 9- through 26-year-old girls and women (GARDASIL N = 10,723; AAHS control or saline placebo N = 9409) and 5417 9- through 26-year-old boys and men (GARDASIL N = 3109; AAHS control or saline placebo N = 2308).

Type-specific immunoassays with type-specific standards were used to assess immunogenicity to each vaccine HPV type. These assays measured antibodies against neutralizing epitopes for each HPV type. The scales for these assays are unique to each HPV type; thus, comparisons across types and to other assays are not appropriate.

Immune Response to GARDASIL

The primary immunogenicity analyses were conducted in a per-protocol immunogenicity (PPI) population. This population consisted of individuals who were seronegative and PCR negative to the relevant HPV type(s) at enrollment, remained HPV PCR negative to the relevant HPV type(s) through 1 month postdose 3 (month 7), received all 3 vaccinations, and did not deviate from the study protocol in ways that could interfere with the effects of the vaccine.

Immunogenicity was measured by (1) the percentage of individuals who were seropositive for antibodies against the relevant vaccine HPV type, and (2) the Geometric Mean Titer (GMT).

In clinical studies in girls and women, at least 99.8%, 99.8%, 99.8%, and 99.5% who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month postdose 3 across all age groups tested.

In clinical studies in boys and men, at least 98.9%, 99.2%, 98.8%, and 97.4% who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month postdose 3 across all age groups tested.

Across all populations, anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs peaked at month 7 (Table 17 and Table 18). GMTs declined through month 24 and then stabilized through month 36 at levels above baseline. Table 19 displays the persistence of anti-HPV cLIA geometric mean titers by gender and age group. The duration of immunity following a complete schedule of immunization with GARDASIL has not been established.

Table 17

Summary of Month 7Anti-HPV cLIA Geometric Mean Titers in the PPI* Population of Girls and Women

Population   N**   n***   % Seropositive
(95% CI)
  GMT
(95% CI) mMU/mL
Anti-HPV 6
9- through 15-year-old girls   1122   917   99.9 (99.4, 100.0)   929.2 (874.6, 987.3)
16- through 26-year-old girls and women   9862   3333   99.8 (99.6, 99.9)   545.2 (530.3, 560.6)
Anti-HPV 11
9- through 15-year-old girls   1122   917   99.9 (99.4, 100.0)   1304.6 (1224.7, 1389.7)
16- through 26-year-old girls and women   9862   3357   99.8 (99.5, 99.9)   749.0 (726.1, 772.7)
Anti-HPV 16
9- through 15-year-old girls   1122   915   99.9 (99.4, 100.0)   4918.5 (4556.6, 5309.1)
16- through 26-year-old girls and women   9862   3253   99.8 (99.6, 100.0)   2411.3 (2311.1, 2515.9)
Anti-HPV 18
9- through 15-year-old girls   1122   922   99.8 (99.2, 100.0)   1042.6 (967.6, 1123.3)
16- through 26-year-old girls and women   9862   3571   99.4 (99.1, 99.7)   475.6 (459.2, 492.6)
*The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).
**Number of individuals randomized to the respective vaccination group who received at least 1 injection.
***Number of individuals contributing to the analysis.
cLIA = Competitive Luminex immunoassay
CI = Confidence interval
GMT = Geometric mean titers
(†)mMU = milli-Merck units
 

Table 18

Summary of Month 7 Anti-HPV cLIA Geometric Mean Titers in the PPI* Population of Boys and Men

Population   N**   n***   % Seropositive
(95% CI)
  GMT
(95% CI) mMU/mL
Anti-HPV 6
9- through 15-year-old boys   1072   884   99.9 (99.4, 100.0)   1037.5 (963.5, 1117.3)
16- through 26-year-old boys and men   2026   1094   98.9 (98.1, 99.4)   447.2 (418.4, 477.9)
Anti-HPV 11
9- through 15-year-old boys   1072   885   99.9 (99.4, 100.0)   1386.8 (1298.5, 1481.0)
16- through 26-year-old boys and men   2026   1094   99.2 (98.4, 99.6)   624.5 (588.6, 662.5)
Anti-HPV 16
9- through 15-year-old boys   1072   882   99.8 (99.2, 100.0)   6056.5 (5601.4, 6548.6)
16- through 26-year-old boys and men   2026   1137   98.8 (97.9, 99.3)   2401.5 (2241.8, 2572.6)
Anti-HPV 18
9- through 15-year-old boys   1072   887   99.8 (99.2, 100)   1357.4 (1249.4, 1474.7)
16- through 26-year-old boys and men   2026   1176   97.4 (96.3, 98.2)   402.6 (374.6, 432.6)
*The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).
**Number of individuals randomized to the respective vaccination group who received at least 1 injection.
***Number of individuals contributing to the analysis.
cLIA = Competitive Luminex immunoassay
CI = Confidence interval
GMT = Geometric mean titers
(†)mMU = milli-Merck units
 

Table 19

Persistence of Anti-HPV cLIA Geometric Mean Titers by Gender and Age Group

Assay (cLIA)/ Time Point 9- to 15-year-old Boys

(N* = 1072)

16- to 26-year-old Boys and Men

(N* = 2026)

9- to 15-year-old Girls

(N* = 1122)

16- to 26-year-old Girls and Women

(N* = 9859)

n** GMT
(95% CI) mMU/mL***
n** GMT
(95% CI) mMU/mL***
n** GMT
(95% CI) mMU/mL***
n** GMT
(95% CI) mMU/mL***
Anti-HPV 6
Month 07 884 1037.5

(963.5, 1117.3)

1094 447.2

(418.4, 477.9)

917 929.2

(874.6, 987.3)

3333 545.2

(530.3, 560.6)

Month 24 323 134.1

(119.5, 150.5)

907 80.3

(74.9, 86.0)

214 156.1

(135.6, 179.6)

2792 109.1

(105.2, 113.1)

Month 36 342 126.6

(111.9, 143.2)

654 72.4

(68.0, 77.2)

356 129.4

(115.6, 144.8)

- -
Month 48 - - - - - - 2375 74.6

(71.6, 77.7)

Anti-HPV 11
Month 07 885 1386.8

(1298.5, 1481.0)

1094 624.5

(588.6, 662.5)

917 1304.6

(1224.7, 1389.7)

3357 749.0

(726.1, 772.7)

Month 24 324 188.5

(168.4, 211.1)

907 94.6

(88.4, 101.2)

214 218.0

(188.3, 252.4)

2821 137.0

(132.0, 142.2)

Month 36 342 148.8

(131.1, 169.0)

654 80.3

(75.7, 85.2)

356 148.0

(131.1, 167.1)

- -
Month 48 - - - - - - 2399 90.3

(86.6, 94.1)

Anti-HPV 16
Month 07 882 6056.5

(5601.4, 6548.6)

1137 2401.5

(2241.8, 2572.6)

915 4918.5

(4556.6, 5309.1)

3253 2411.3

(2311.1, 2515.9)

Month 24 322 938.2

(825.0, 1067.0)

938 347.7

(322.5, 374.9)

211 944.2

(804.4, 1108.3)

2725 442.6

(425.0, 460.9)

Month 36 341 708.8

(613.9, 818.3)

672 306.7

(287.5, 327.1)

353 642.2

(562.8, 732.8)

- -
Month 48 - - - - - - 2330 334.6

(319.4, 350.5)

Anti-HPV 18
Month 07 887 1357.4

(1249.4, 1474.7)

1176 402.6

(374.6, 432.6)

922 1042.6

(967.6, 1123.3)

3571 475.6

(459.2, 492.6)

Month 24 324 131.9

(112.1, 155.3)

967 38.7

(35.2, 42.5)

214 137.7

(114.8, 165.1)

3007 50.8

(48.2, 53.5)

Month 36 343 113.0

(94.7, 135.0)

690 33.4

(30.9, 36.1)

357 87.0

(74.8, 101.2)

- -
Month 48 - - - - - - 2536 33.8

(32.0, 35.7)

*N = Number of individuals randomized in the respective group who received at least 1 injection.
**n = Number of individuals in the indicated immunogenicity population.
***mMU = milli-Merck units per mL

(†)Month 36 time point for 16- to 26-year-old boys and men; Month 37 for 9- to 15-year-old boys and girls. No serology samples were collected
at this time point for 16- to 26-year-old girls and women.

(‡)Month 48/End-of-study visits for 16- to 26-year-old girls and women were generally scheduled earlier than Month 48. Mean visit timing was
Month 44. The studies in 9- to 15-year-old boys and girls and 16- to 26-year-old boys and men were planned to end prior to 48 months and
therefore no serology samples were collected.

cLIA = Competitive Luminex immunoassay
CI = Confidence interval
GMT = Geometric mean titers

Tables 17 and 18 display the Month 7 immunogenicity data for girls and women and boys and men. Anti-HPV responses 1 month postdose 3 among 9- through 15-year-old adolescent girls were non-inferior to anti-HPV responses in 16- through 26-year-old girls and women in the combined database of immunogenicity studies for GARDASIL. Anti-HPV responses 1 month postdose 3 among 9- through 15-year-old adolescent boys were non-inferior to anti-HPV responses in 16- through 26-year-old boys and men in Study 5.

On the basis of this immunogenicity bridging, the efficacy of GARDASIL in 9- through 15-year-old adolescent girls and boys is inferred.

GMT Response to Variation in Dosing Regimen in 18- Through 26-Year-Old Women

Girls and women evaluated in the PPE population of clinical studies received all 3 vaccinations within 1 year of enrollment. An analysis of immune response data suggests that flexibility of ±1 month for Dose 2 (i.e., Month 1 to Month 3 in the vaccination regimen) and flexibility of ±2 months for Dose 3 (i.e., Month 4 to Month 8 in the vaccination regimen) do not impact the immune responses to GARDASIL.

Duration of the Immune Response to GARDASIL

The duration of immunity following a complete schedule of immunization with GARDASIL has not been established. The peak anti-HPV GMTs for HPV types 6, 11, 16, and 18 occurred at month 7. Anti-HPV GMTs for HPV types 6, 11, 16, and 18 were similar between measurements at month 24 and month 60 in Study 2.

14.8 Studies with RECOMBIVAX HB

The safety and immunogenicity of co-administration of GARDASIL with RECOMBIVAX HB hepatitis B vaccine (recombinant) (same visit, injections at separate sites) were evaluated in a randomized study of 1871 women aged 16 through 24 years at enrollment. Immune response to both hepatitis B vaccine (recombinant) and GARDASIL was non-inferior whether they were administered at the same visit or at a different visit.

16 HOW SUPPLIED/STORAGE AND HANDLING

All presentations for GARDASIL contain a suspension of 120 mcg L1 protein from HPV types 6, 11, 16, and 18 in a 0.5-mL dose. GARDASIL is supplied in vials and syringes.

Carton of one 0.5-mL single-dose vial, NDC 0006-4045-00.

Carton of ten 0.5-mL single-dose vials, NDC 0006-4045-41.

Carton of six 0.5-mL single-dose prefilled Luer Lock syringes, preassembled with UltraSafe Passive®2 delivery system. One-inch, 25-gauge needles are provided separately in the package. NDC 0006-4109-06.

Carton of six 0.5-mL single-dose prefilled Luer Lock syringes with tip caps. NDC 0006-4109-09.

Store refrigerated at 2 to 8°C (36 to 46°F). Do not freeze. Protect from light.

GARDASIL should be administered as soon as possible after being removed from refrigeration.

GARDASIL can be out of refrigeration (at temperatures at or below 25°C/77°F), for a total time of not more than 72 hours.

17 PATIENT COUNSELING INFORMATION

[See FDA-Approved Patient Labeling (17.2).]

17.1 Information for the Patient, Parent, or Guardian

Inform the patient, parent, or guardian:

  • Vaccination does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care.
  • GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity.
  • Since syncope has been reported following vaccination sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended.
  • Vaccine information is required to be given with each vaccination to the patient, parent, or guardian.
  • Information regarding benefits and risks associated with vaccination.
  • GARDASIL is not recommended for use in pregnant women.
  • Importance of completing the immunization series unless contraindicated.
  • Report any adverse reactions to their health care provider.

17.2 FDA-Approved Patient Labeling

Manufactured and Distributed by:

MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

Printed in USA

9883612

1 Registered trademark of MERCK & CO., Inc. Whitehouse Station, NJ 08889, USA COPYRIGHT © 2006, 2009 MERCK & CO., Inc. All rights reserved

2 UltraSafe Passive® delivery system is a Trademark of Safety Syringes, Inc.

9883612

USPPI

Patient Information about

GARDASIL® (pronounced “gard-Ah-sill”)

Generic name: [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Read this information with care before getting GARDASIL1. You (the person getting GARDASIL) will need 3 doses of the vaccine. It is important to read this leaflet when you get each dose. This leaflet does not take the place of talking with your health care provider about GARDASIL.

What is GARDASIL?

GARDASIL is a vaccine (injection/shot) that is used for girls and women 9 through 26 years of age to help protect against the following diseases caused by Human Papillomavirus (HPV):

  • Cervical cancer
  • Vulvar and vaginal cancers
  • Genital warts
  • Abnormal and precancerous cervical, vaginal, and vulvar lesions
    • The diseases listed above have many causes, and GARDASIL only protects against diseases caused by certain kinds of HPV (called Type 6, Type 11, Type 16, and Type 18). Most of the time, these 4 types of HPV are responsible for the diseases listed above.
    • GARDASIL cannot protect you from a disease that is caused by other types of HPV, other viruses, or bacteria.
    • GARDASIL does not treat HPV infection.
    • You cannot get HPV or any of the above diseases from GARDASIL.

GARDASIL is used for boys and men 9 through 26 years of age to help protect against genital warts.

What important information about GARDASIL should I know?

  • You should continue to get routine cervical cancer screening.
  • GARDASIL may not fully protect everyone who gets the vaccine.
  • GARDASIL will not protect against HPV types that you already have.

Who should not get GARDASIL?

You should not get GARDASIL if you have, or have had:

  • an allergic reaction after getting a dose of GARDASIL.
  • a severe allergic reaction to yeast, amorphous aluminum hydroxyphosphate sulfate, polysorbate 80.

What should I tell my health care provider before getting GARDASIL?

Tell your health care provider if you:

  • are pregnant or planning to get pregnant. GARDASIL is not recommended for use in pregnant women.
  • have immune problems, like HIV infection, cancer, or you take medicines that affect your immune system.
  • have a fever over 100°F (37.8°C).
  • had an allergic reaction to another dose of GARDASIL.
  • take any medicines, even those you can buy over the counter.

Your health care provider will help decide if you should get the vaccine.

How is GARDASIL given?

GARDASIL is a shot that is usually given in the arm muscle. You will need 3 shots given on the following schedule:

  • Dose 1: at a date you and your health care provider choose.
  • Dose 2: 2 months after Dose 1.
  • Dose 3: 6 months after Dose 1.

Fainting can happen after getting GARDASIL. Sometimes people who faint can fall and hurt themselves. For this reason, your health care provider may ask you to sit or lie down for 15 minutes after you get GARDASIL. Some people who faint might shake or become stiff. This may require evaluation or treatment by your health care provider.

Make sure that you get all 3 doses on time so that you get the best protection. If you miss a dose, talk to your health care provider.

What are the possible side effects of GARDASIL?

The most common side effects with GARDASIL are:

  • pain, swelling, itching, bruising, and redness at the injection site
  • headache
  • fever
  • nausea
  • dizziness
  • vomiting
  • fainting

Tell your health care provider if you have any of the following problems because these may be signs of an allergic reaction:

  • difficulty breathing
  • wheezing (bronchospasm)
  • hives
  • rash

Tell your health care provider if you have:

  • swollen glands (neck, armpit, or groin)
  • joint pain
  • unusual tiredness, weakness, or confusion
  • chills
  • generally feeling unwell
  • leg pain
  • shortness of breath
  • chest pain
  • aching muscles
  • muscle weakness
  • seizure
  • bad stomach ache
  • bleeding or bruising more easily than normal

Contact your health care provider right away if you get any symptoms that concern you, even several months after getting the vaccine.

For a more complete list of side effects, ask your health care provider.

What are the ingredients in GARDASIL?

The ingredients are proteins of HPV Types 6, 11, 16, and 18, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, polysorbate 80, sodium borate, and water for injection.

This leaflet is a summary of information about GARDASIL. If you would like more information, please talk to your health care provider or visit www.gardasil.com.

Manufactured and Distributed by: MERCK & CO., Inc.

Whitehouse Station, NJ 08889, USA

Issued October 2009

______________________________

1 Registered trademark of MERCK & CO., Inc. Whitehouse Station, NJ 08889, USA

COPYRIGHT © 2006, 2009 MERCK & CO., Inc.
All rights reserved

Contacts

Merck & Co., Inc.
Media:
Pam Eisele, 908-423-5042
Jennifer Allen Woodruff, 215-652-0572
or
Investors:
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5088

Contacts

Merck & Co., Inc.
Media:
Pam Eisele, 908-423-5042
Jennifer Allen Woodruff, 215-652-0572
or
Investors:
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5088